Menu
Recruiting NCT07681466

Chronology and Sequence of Premonitory Symptoms

Observational Migraine

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Migraine. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Chronology and Sequence of Premonitory Symptoms to Understand How Migraine Attack Starts: the CHRONOpS Study

Overview

The purpose of this study is to prospectively investigate the temporal sequence of premonitory symptoms across multiple migraine attacks.

Detailed description

The premonitory phase marks the transition from the interictal to the headache phase and is considered the beginning of the migraine attack. During this phase, changes in brain activity and network connectivity give rise to non-headache symptoms (premonitory symptoms) that precede pain.

Premonitory symptoms (PSs) are reported by a substantial proportion of individuals with migraine, with prevalence estimates ranging widely across studies, from approximately 29% in population-based to 66% in clinic-based settings, a variability largely dependent on the method of assessment. Although neuroimaging studies have consistently shown hypothalamic activation during the premonitory phase, activation of other areas may also be observed. However, neuroimaging studies have been mostly limited by their reliance on time-based criteria to define the premonitory phase and by insufficient temporal resolution to capture the sequential activation of brain regions within the same phase.

To date, the temporal sequence of events at migraine onset remains unknown and clinical evaluation of symptoms remains the most reliable approach to reconstructing the sequence of events underlying migraine initiation. Recent evidence supports the efficacy of treating the migraine attack during the prodrome. However, the lack of prospective data on the temporal ordering of premonitory symptoms represents a critical gap.

This study will prospectively investigate the temporal sequence of premonitory symptoms across multiple migraine attacks, addressing a critical gap in our understanding of early attack dynamics. By identifying consistent early symptoms and their progression, we aim to define clinically actionable windows for early intervention and provide indirect insight into the sequence of brain network activation underlying migraine onset.

PSs will be collected prospectively. Participants will record premonitory symptoms using a structured electronic diary across a maximum of 5 migraine attacks. They will be instructed to complete the diary at headache onset as early as possible, with timestamped entries to minimise recall bias. Data will be collected using an ad hoc electronic diary developed on the REDCap platform and a standardised case report form (CRF). The diary will collect information on the type, sequence, onset, and duration of PSs experienced before the pain phase.

Primary outcome measures

  • Frequency of each symptom as the first premonitory symptom [Time frame: Up to 6 months]
Secondary outcome measures (7)
  • Time from onset of each premonitory symptom to headache onset (categorical intervals) [Time frame: up to 6 months]
  • Time from onset of each premonitory symptom to headache onset (minutes) [Time frame: Up to 6 months]
  • Intra-subject consistency of premonitory symptoms across attacks [Time frame: Up to 6 months]
  • Evolution and persistence of premonitory symptoms during the headache phase [Time frame: Up to 6 months]
  • Patient-level agreement between clinically reported and prospectively recorded presence of premonitory symptoms [Time frame: Up to 6 months]
  • Symptom-level concordance between baseline-reported and attack-recorded premonitory symptoms [Time frame: Up to 6 months]
  • Premonitory-phase disability and the symptom responsible [Time frame: Up to 6 months]

Eligibility criteria

Inclusion criteria

  • Diagnosis of episodic (EM) or chronic migraine (CM) or CM with medication overuse headache (MOH) according to ICHD-III criteria;
  • Age between 18 and 65 years;
  • At least 2 migraine days (MMD) in the month preceding the inclusion;
  • Migraine history of at least 12 months prior to inclusion
  • Signed written informed consent.

Exclusion criteria

  • History or current diagnosis of secondary headache disorders as defined by ICHD-III;
  • History of other neurological comorbidities or major psychiatric disorders;
  • History of migraine for < 12 months prior to the inclusion;
  • Opioid overuse according to the ICHD-III criteria;
  • Pregnancy or breastfeeding.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Italy · 1 center
  • Sapienza University of Rome, Polo Pontino, centro cefalee, ICOT — Latina

Publications

  • Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, Yu SY, Severt L, Finnegan M, Trugman JM. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023 Dec 16;402(10419):2307-2316. doi: 10.1016/S0140-6736(23)01683-5. Epub 2023 Nov 15. PMID 37979595
  • Messina R, Rocca MA, Goadsby PJ, Filippi M. Insights into migraine attacks from neuroimaging. Lancet Neurol. 2023 Sep;22(9):834-846. doi: 10.1016/S1474-4422(23)00152-7. Epub 2023 Jul 18. PMID 37478888
  • Karsan N, Goadsby PJ. Neuroimaging in the pre-ictal or premonitory phase of migraine: a narrative review. J Headache Pain. 2023 Aug 11;24(1):106. doi: 10.1186/s10194-023-01617-x. PMID 37563570
  • Eigenbrodt AK, Christensen RH, Ashina H, Iljazi A, Christensen CE, Steiner TJ, Lipton RB, Ashina M. Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency. J Headache Pain. 2022 Nov 12;23(1):140. doi: 10.1186/s10194-022-01510-z. PMID 36371152
  • Sebastianelli G, Atalar AC, Cetta I, Farham F, Fitzek M, Karatas-Kursun H, Kholodova M, Kukumagi KH, Montisano DA, Onan D, Pantovic A, Skarlet J, Sotnikov D, Caronna E, Pozo-Rosich P; International Headache Academy of the International Headache Society (IHS-iHEAD). Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis. Cephalalgia. 2024 Oct;44(10):33 PMID 39380339

Identifiers

NCT: NCT07681466 · CHRONO-PS-26

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗